Activation of JAK-STAT and nitric oxide signaling as a mechanism for donor heart dysfunction

Christian F Bulcao1, Karen M D'Souza, Ricky Malhotra

  • 1Department of Surgery, Section of Cardiothoracic Surgery, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.

Insights

Donor heart dysfunction involves increased interleukin-6 (IL-6) signaling, which impairs cardiac function. Targeting this pathway may improve heart transplant outcomes.

Area of Science:

  • Cardiology
  • Immunology
  • Molecular Biology

Background:

  • Donor heart dysfunction (DHD) affects up to 25% of brain-dead (BD) donors, hindering heart transplantation.
  • The molecular mechanisms underlying DHD are not fully understood.
  • This study investigates the role of interleukin-6 (IL-6) signaling via JAK2-STAT3 in DHD.

Purpose of the Study:

  • To investigate the role of myocardial IL-6 signaling through the JAK2-STAT3 pathway in donor heart dysfunction (DHD).
  • To determine the relationship between IL-6, JAK2-STAT3 signaling, nitric oxide (NO) production, and cardiac myocyte contractility in DHD.
  • To explore the potential of targeting iNOS as a therapeutic strategy for DHD.

Main Methods:

  • Hearts from 14 donors with DHD (LV ejection fraction <35%) and 10 normal function (NF) controls were analyzed.
  • Myocardial IL-6, phosphorylated STAT3, inducible NO synthase (iNOS), and caspase-3 levels were quantified.
  • Enzyme-linked immunoassay (ELISA) and activity assays were employed.

Main Results:

  • Myocardial IL-6 was 8-fold higher in DHD hearts compared to NF controls.
  • Phosphorylated STAT3 expression was 5-fold higher in DHD, indicating increased JAK2-STAT3 signaling.
  • iNOS activity increased 2.5-fold, and pro-apoptotic markers (Bnip3, caspase-3) were elevated in DHD hearts.

Conclusions:

  • Elevated myocardial IL-6 expression is associated with DHD.
  • Increased JAK2-STAT3 signaling and subsequent iNOS upregulation contribute to decreased cardiac contractility.
  • Targeting iNOS signaling presents a potential therapeutic avenue to improve cardiac function in DHD for better heart transplantation outcomes.
Abstract

Related Concept Videos

Nitric Oxide Signaling Pathway01:28

Nitric Oxide Signaling Pathway

Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure to...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...